Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). ...
Jun 15, 2022
0
5
Scientists have reported good news on the pandemic preparedness front: A cocktail of four manufactured antibodies is effective at neutralizing a virus from the Henipavirus family, a group of pathogens considered to be a global ...
Jun 13, 2022
0
111
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute ...
Jun 5, 2022
0
108
An international team led by a physician from the Karl Landsteiner University for Health Sciences, Krems, describes for the first time a mutation of the IL-33 gene in the human genome that results in multiple allergic disease ...
May 27, 2022
0
314
A case report published in the New England Journal of Medicine provides evidence that enterovirus D68 directly infects spinal cord neurons and that a corresponding robust immune response is present—a direct causation to ...
May 26, 2022
0
77
A UCLA-led team of researchers studying the effect of the monoclonal antibody Leronlimab on long COVID-19 may have found a surprising clue to the baffling syndrome, one that contradicts their initial hypothesis. An abnormally ...
Apr 22, 2022
1
675
SARS-CoV-2, the virus that causes COVID-19, has continuously mutated since it emerged in late 2019. This rapid evolution poses challenges for vaccines and treatments designed to target the virus. A booster shot is now needed ...
Apr 16, 2022
0
4
There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité-Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms ...
Apr 13, 2022
0
4
For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitalization or death ...
Apr 12, 2022
0
3
A group of 36 volunteers have completed the first human challenge study of COVID-19, after being given the virus and then monitored to examine what happened to them after infection.
Apr 1, 2022
0
296
